摘要
This article summarizes the major new findings on clinical management for benign prostatic hyperplasia （BPH） that were presented at the annual meeting of the American Urological Association （AUA） in May 2008. The management of symptomatic BPH has been changed significantly over the last decade in response to the availability of new treatment options. Prior to the 1980s, open prostatectomy was the only widely accepted intervention for BPH. Since then, the advent of new medical therapies for BPH and the introduction of a range of minimally invasive therapies have provided for men with lower urinary tract symptoms （LUTS） secondary to BPH.1 In this year＇s AUA meeting, several new findings were reported in the filed of BPH which involved epidemiology, clinical progression, drug therapy and new technologies in surgical therapy of BPH.
This article summarizes the major new findings on clinical management for benign prostatic hyperplasia （BPH） that were presented at the annual meeting of the American Urological Association （AUA） in May 2008. The management of symptomatic BPH has been changed significantly over the last decade in response to the availability of new treatment options. Prior to the 1980s, open prostatectomy was the only widely accepted intervention for BPH. Since then, the advent of new medical therapies for BPH and the introduction of a range of minimally invasive therapies have provided for men with lower urinary tract symptoms （LUTS） secondary to BPH.1 In this year＇s AUA meeting, several new findings were reported in the filed of BPH which involved epidemiology, clinical progression, drug therapy and new technologies in surgical therapy of BPH.
